Who Can You Help Escape High LDL-C?

Repatha® is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (CVD) who require additional lowering of low density lipoprotein cholesterol (LDL-C).1

Is your patient’s LDL-C still too high?

Is your patient on max tolerated statin therapy, as an adjunct to diet?

Maximally tolerated statin therapy includes patients who are on the maximum dose of statin, are on less than the maximum dose of a statin due to tolerability, or cannot tolerate any statin type or dose.

Does your patient have a history of clinical ASCVD?

Clinical ASCVD* includes: MI, PAD, stroke or transient ischemic attack, or other clinical indicators.2

Learn More

Patients with clinical ASCVD may have had one or more of the following, as defined by the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Guidelines:2,*

Ultimately, the diagnosis of clinical ASCVD is determined based on the medical judgment of the clinician.

Image of patient with clinical ASCVD
Image of patient with clinical ASCVD

*Per the 2013 ACC/AHA Guidelines, clinical ASCVD includes history of MI, stable or unstable angina, PAD, stroke or TIA, coronary or other arterial revascularization, and acute coronary syndromes.

Repatha® is also appropriate for patients with heterozygous familial hypercholesterolemia (HeFH) who are on a maximally tolerated statin as an adjunct to diet and require additional LDL-C lowering.1

HeFH is an inherited condition that causes high levels of LDL-C and can be diagnosed using the Simon Broome diagnostic criteria.3,†

In adults, the Simon Broome criteria include an LDL-C of > 190 mg/dL (without therapy) plus clinical criteria (including patient or family history of tendon xanthomas, plus either family history of early CAD or family history of total cholesterol > 290 mg/dL).4

ACC = American College of Cardiology; ACS = acute coronary syndromes; ASCVD = atherosclerotic cardiovascular disease; CAD = coronary artery disease; LDL-C = low density lipoprotein cholesterol; MI = myocardial infarction; PAD = peripheral artery disease; TIA = transient ischemic attack.

References: 1. Repatha® (evolocumab) Prescribing Information, Amgen. 2. Stone NJ, Robinson JG, Lichtenstein AH, et al. Circulation. 2014;129:S1-S45. 3. Raal FJ, Stein EA, Dufour R, et al. Lancet. 2015;385:331-340. 4. Scientific Steering Committee on behalf of the Simon Broome Register Group. Br Med J. 1991;303:893-896.

IMPORTANT SAFETY INFORMATION

See More

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®.

Allergic reactions: Hypersensitivity reactions (e.g. rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hyperlipidemia, including HeFH: The most common adverse reactions (> 5% of Repatha®-treated patients and occurring more frequently than placebo) in clinical trials in primary hyperlipidemia (including HeFH) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

In a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% of Repatha®-treated patients and 1% of placebo-treated patients. The most common adverse reaction that led to Repatha® treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for Repatha® and placebo, respectively).

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in Repatha®-treated patients and placebo-treated patients were 0.1% and 0%, respectively.

Allergic reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse reactions in the Cardiovascular Outcomes trial: The safety profile of Repatha® in this trial was generally consistent with the safety profile described above in the 12- and 52-week controlled trials involving patients with primary hyperlipidemia (including HeFH). Serious adverse events occurred in 24.8% and 24.7% of Repatha®-treated and placebo-treated patients, respectively. Adverse events led to discontinuation of study treatment in 4.4% of patients assigned to Repatha® and 4.2% assigned to placebo. Common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) included diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha® compared with 7.7% in those assigned to placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with Repatha®.

Please see full Prescribing Information.

Back to Top

What is PCSK9?

Close

Why Repatha® Inhibits PCSK9

Close

How Repatha® Lowers LDL-C Levels

Close

Using the Pushtronex® System

Close

Using the SureClick® Autoinjector

Close
Close